secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2025-02-03T23:59:59+00:00
Accession:  0001437749-25-002610
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharma secures $27M financing for subsidiary Hope Therapeutics clinic rollup
--------------------------------------------------------------------------------

- Private placement of 732,600 shares at $2.73/share for $2M immediate funding.
- Investor committed to $25M in Hope Series A Preferred convertible into 1/3 equity, 15% dividend, non-callable for 2 years.
- First $6.75M tranche of Hope investment due by Feb 7, 2025; remaining $18.25M by Apr 1, 2025.
- Funds to acquire Kadima Neuropsychiatry and start nationwide interventional psychiatry clinic rollup.
- Company anticipates pro-forma revenue of ~$100M by end of 2025 using bank leverage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925002610/0001437749-25-002610-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925002610/nrxp20250203_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-002610

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer